Specifically, on December 19, 2013, the USPTO found that all claims of TSI’s patent are unpatentable. As is customary, the Office has issued a Right of Appeal Notice (RAN) allowing 30 days in which TSI may appeal the Examiner’s final decision to the Patent Trial and Appeal Board.
Axbil BioVigilant holds 19 patents with an additional 37 applications pending.
Representing Azbil BioVigilant in its patent litigation is Amster, Rothstein & Ebenstein LLP.